Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: A NICE single technology appraisal

PharmacoEconomics

Volumn 31, Issue 12, 2013, Pages 1121-1129

  Beale, Sophie ^a   Dickson, Rumona ^a   Bagust, Adrian ^a   Blundell, Michaela ^a   Dundar, Yenal ^a   Boland, Angela ^a   Marshall, Ernie ^b   Plummer, Ruth ^c   Proudlove, Chris ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d Pharmacy Practice Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; VEMURAFENIB;

ADULT; ADVANCED CANCER; CANCER RESEARCH; CLINICAL DECISION MAKING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; DISEASE COURSE; ECONOMIC ASPECT; FEMALE; GENE MUTATION; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MELANOMA; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVIEW; TERMINAL CARE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG INDUSTRY; HUMANS; INDOLES; MELANOMA; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84890366609     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0094-x     Document Type: Review

References (23)

1. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal process. 2009. http://www.nice.org.uk/media/913/06/ guide-to-the-sta-proof-6-26-10-09.pdf. Accessed 12 Sept 2013.
2. National Institute for Health and Clinical Excellence. Melanoma (BRAF V600 mutation positive, unresetable metastatic) - vemurafenib (TA269). 2011. http://guidance.nice.org.uk/TA269. Accessed 12 Sept 2013.
3. Dickson R, Bagust A, Boland A, Blundell M, Davis H, Dundar Y, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy. Pharmacoeconomics. 2011;29(12):1-12.
4. Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Beale S, et al. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma. PharmacoEconomics. 2013;31:403-13. doi: 10.1007/s40273-013-0043-8.
5. Parkin D, Mesher D, Sasieni P. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010. Br J Cancer. 2011;31:403-13. doi: 10.1007/s40273-013-0043-8.
6. Cancer Research UK. Skin cancer statistics - UK. 2011. http://info.cancerresearchuk.org/cancerstats/types/skin/. Accessed July 2011.
7. American Joint Committee on Cancer. Melanoma of the skin staging. 7th ed. 2009. http://www.cancerstaging.org/staging/posters/melanoma8.5x11.pdf. Accessed 21 August 2013.
8. NHS England. The Cancer Drugs Fund. http://www.england.nhs.uk/ourwork/ cdf/. Accessed 26 June 2013.
9. Long G, Menzies A, Nagrial A, et al. Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma. Am Soc Clin Oncol. 2010;28(15 Suppl.): abstract 8548.
10. Roche. NICE STA submission: vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation positive malignant melanoma. 2012. http://guidance.nice.org.uk/TA/Wave27/5/Consultation/EvaluationReport/ ManufacturerSubmissions/Roche/pdf/English. Accessed 5 July 2013.
11. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med. 2011;364(26):2507-16.
12. Hoffmann-La Roche I. Clinical study report - BRIM 3. 2011. Data on file.
13. FACITOrg. Questionnaires. http://www.facit.org/FACITOrg/Questionnaires. Accessed 26 June 2013.
14. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med. 2011;364(26):2517-26.
15. Xing Y, Chang G, Hu C, Askew R, Ross M, Gershenwald J, et al. Conditional survival estimates improve over time for patients with advanced melanoma. Cancer. 2010;116:2234-41.
16. Beusterien KM, Szabo SM, Kotapati S, Mukherjee J, Hoos A, Hersey P, et al. Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer. 2009;101(3):387-9.
17. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Live Outcomes. 2008;6:84.
18. Department of Health. National schedule of reference costs 2009-2010. 2011. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-123459. Accessed 22 March 2013.
19. Joint Formulary Committee. British National Formulary. 2011.
20. National Institute for Health and Clinical Excellence. Melanoma (Stage III or IV) - ipilimumab. 2012. http://guidance.nice.org.uk/TA/WaveCRS2/48. Accessed February 2012.
21. Balch C, Gershenwald J, Soong S, Thompson J, Atkins M, Byrd D, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;21:6199-206.
22. Bedikian A, DeConti R, Conry R, Agarwala S, Papadopoulos N, Kim K, et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbaxine in patients with metastatic malignant melanoma. Ann Oncol. 2011;22:787-93.
23. Roche. Vemurafenib for the treatment of BRAF V600 mutation positive metastatic melanoma: manufacturer's response to the first ACD. 2012. http://www.nice.org.uk/nicemedia/live/13579/60480/60480.pdf. Accessed 5 July 2013.